The power of a pill: Ekterly (Sebetralstat): first oral on-demand therapy for hereditary angioedema—a paradigm shift in treatment

Hereditary angioedema: disease overview Hereditary angioedema (HAE) is a rare genetic disorder marked by recurrent, often unpredictable, episodes of localized swelling. It arises from mutations in the C1 esterase inhibitor (C1-INH) gene (SERPING1) in most cases[1,2]. C1-INH normally restrains proteases in the complement and contact systems; deficiency or dysfunction of C1-INH leads to excessive production of bradykinin, a potent vasoactive peptide. The unchecked bradykinin causes transient increases in vascular permeability and tissue edema[2]. Clinically, HAE attacks classically involve non-pitting swelling of the face, abdominal wall, extremities, and genitals without urticarial rash or itching[2]. Edema of the intestinal wall may cause severe colicky pain and vomiting; laryngeal edema can be life-threatening due to airway obstruction[3]. Symptoms typically begin in childhood or early adulthood, though pediatric patients may have delayed onset. Attacks often occur spontaneously but can be precipitated by stress, minor trauma, infection, or certain medications[3]. Importantly, any laryngeal attack poses a risk of fatal asphyxiation if not promptly treated, underscoring the grave potential of HAE. The inherited pattern of classic HAE types I and II is autosomal dominant[3]. Type I (≈85% of cases) is defined by low levels of functional C1-INH, while type II (≈15%) has normal or elevated levels of dysfunctional C1-INH[2]. Both arise from SERPING1 mutations. A third category, often termed HAE with normal C1-INH, includes patients without C1-INH deficiency but with other mutations (e.g., factor XII, plasminogen) or hormonal triggers[3]. The prevalence of HAE is on the order of 1–2 per 50,000 people worldwide[2,3], with some regional variation (approximately 1.1–1.6/50,000 reported in North America and Europe)[2]. Because 20–25% of cases result from de novo mutations, family history is not always present[3]. The disorder is rare but disabling; even the “baseline” quality of life is reduced by the fear of attacks. Diagnostically, low complement C4 and low functional C1-INH confirm the diagnosis of HAE-I/II. By contrast, patients with HAE-normal C1-INH have normal C4/C1 and require genetic or clinical diagnosis[3,4]. Over the past two decades, new therapies have dramatically expanded options for both acute and prophylactic management of HAE, yet gaps remain. Acute attacks have been treated with biologics that replace or mimic C1-INH activity or block the bradykinin pathway. These include plasma-derived or recombinant C1-INH concentrates (e.g., Berinert), a bradykinin B2-receptor antagonist (Firazyr), and a kallikrein inhibitor (ecallantide)[2,5]. Long-term prophylaxis is achieved with regular C1-INH infusions or with newer agents such as lanadelumab (a monoclonal antibody against kallikrein) and the oral kallikrein inhibitor berotralstat (Orladeyo)[5,6]. Other supportive measures (e.g., androgens, anti-fibrinolytics) are rarely used due to limited efficacy or side effects. Despite these advances, all current on-demand therapies require injection or infusion, which can delay treatment and inconvenience patients. Moreover, the burden of self-injectable therapies often leads to delayed dosing—untreated swelling can become more severe during wait times. Oral medications have the potential to reduce treatment burden and improve adherence and quality of life[6]. Nevertheless, until 2025 no pill existed for treating an acute HAE episode, leaving an unmet need for a fast-acting, patient-friendly on-demand option. This article is in accordance with TITAN Guidelines Checklist 2025[7]. Ekterly (Sebetralstat): clinical trials and FDA approval On 7 July 2025, the FDA approved Ekterly (sebetralstat) as the first and only oral on-demand treatment for HAE attacks in patients aged 12 years and older[8,9]. Sebetralstat is a small-molecule inhibitor of plasma kallikrein, the enzyme that generates bradykinin from high-molecular-weight kininogen. By blocking kallikrein, Ekterly disrupts the bradykinin-forming cascade and thus attenuates the excessive vascular leak that underlies an HAE attack[10,11]. This new approval follows promising clinical trials demonstrating rapid symptom relief and a favorable safety profile[12]. The pivotal KONFIDENT phase III trial was a randomized, double-blind, placebo-controlled, three-way crossover study of Ekterly in 136 HAE patients (aged 12 or above) experiencing acute attacks[12]. Subjects were assigned to take a single 300 mg or 600 mg dose of Ekterly (given as one or two oral tablets) or placebo at the onset of an attack. The trial’s primary endpoint was time to onset of symptom relief (defined by patient global impression of change). Both Ekterly doses significantly shortened this time compared to placebo. Median time to feeling “a little better” was only 1.61 hours with 300 mg and 1.79 hours with 600 mg, versus 6.72 hours on placebo[12]. Secondary endpoints likewise favored Ekterly: median time to reduction in severity and to complete attack resolution were significantly faster on active drug. By 24 hours post-dose, about 42.5% of attacks in the 300 mg group and 49.5% in the 600 mg group had fully resolved, versus 27.4% in the placebo[12]. Importantly, Ekterly was well tolerated; adverse events were generally mild, headache being the most common (occurring more often than with placebo)[10], and no new safety signals emerged. In addition, an open-label extension study (KONFIDENT-S) showed that patients could treat emerging attacks very quickly. As of late 2024, patients reported taking Ekterly within a median of 10 minutes of symptom onset and achieving symptom relief in a median of 1.3 hours, even for severe attacks such as laryngeal or severe abdominal episodes[13]. No serious adverse events were noted in over 1,700 treated attacks, confirming a safety profile consistent with placebo[13]. Based on these data, the FDA cleared Ekterly (fast-tracked as an orphan drug) for use at the first sign of an HAE attack[8,14]. Under the approved regimen, patients take Ekterly tablets orally at attack onset. If symptoms persist or worsen, a second identical dose may be taken at least three hours later. The convenience of an oral tablet allows patients to self-administer immediately, even outside the home, potentially transforming the timing and autonomy of acute therapy. Ekterly provides patients and physicians with an important advance[8]. Ekterly is indicated for on-demand use in adolescents and adults (≥12 years). Treatment should begin at the first signs of swelling. The recommended dose is 300 mg (four 75 mg tablets) or 600 mg (eight tablets) of sebetralstat, taken orally; presumably, physicians will start with 300 mg for most attacks. If symptoms are insufficiently relieved, an additional dose may be given no sooner than three hours after the first[10]. No dosage adjustment is required for renal or hepatic impairment in the approved population (per product labeling). Healthcare providers must ensure that patients have prompt access to Ekterly and understand how to use it promptly. Common side effects noted in trials include headache and nasopharyngitis, similar to placebo rates; no serious treatment-related adverse events were observed[10,12]. In particular, no anaphylaxis or hepatic toxicity has been seen. This contrasts with some injectable therapies (ecallantide carries a small anaphylaxis risk) and eliminates needle-related complications[2,5]. Overall, the safety and oral route suggest a favorable risk-benefit profile. The approval of Ekterly marks a major milestone. It is the first new acute HAE therapy in over a decade and the first oral on-demand option[8,11]. By enabling ultra-early treatment, Ekterly may reduce the overall burden of HAE and prevent complications. This aligns with current guidelines urging prompt intervention. The company has not disclosed official wholesale pricing in public sources, but analysts projected Ekterly could generate on the order of several hundred million dollars per year at peak sales[8]. Patients will likely access Ekterly through insurance with cost offset assistance programs. The approved indication does not yet include younger children (<12 years), although pediatric studies in progress may expand use. Looking ahead, the HAE therapeutic field remains vibrant. Other new therapies are in late development, including antisense oligonucleotide and gene editing approaches. For instance, an investigational RNA therapy targeting prekallikrein is nearing FDA review, and a CRISPR gene-editing therapy targeting kallikrein production is in clinical trials[6]. Monoclonal kallikrein inhibitors are also entering phase III testing[6]. Conclusion The FDA approval of Ekterly sets in a new era for HAE management by making an oral on-demand option clinically available. This breakthrough directly addresses longstanding limitations of injectable therapies, offering rapid, convenient relief of acute swelling episodes. The robust Phase III data demonstrate that Ekterly effectively speeds symptom relief with minimal toxicity, and early clinical experience should clarify its role as first-line acute therapy. As providers integrate this option, they must continue emphasizing comprehensive care: early treatment of attacks, consideration of prophylaxis for high-risk patients, and ongoing patient education. With Ekterly’s entry, patients with HAE—who have long endured the unpredictability of attacks and treatment hurdles—now have greater control. The coming years will reveal how Ekterly fits alongside prophylactic innovations and how emerging therapies further reshape the landscape. For now, Ekterly stands as a landmark advance, turning the page to a patient-centric model where an HAE attack can be treated as easily as taking a pill.